Niagen Bioscience (NAGE) Cost of Revenue (2010 - 2026)

Niagen Bioscience (NAGE) has 17 years of Cost of Revenue data on file, last reported at $11.5 million in Q1 2026.

• On a quarterly basis, Cost of Revenue rose 364.0% year-over-year to $11.5 million in Q1 2026; TTM through Mar 2026 was $30.0 million, a 20.45% increase from a year earlier, with the FY2025 full-year figure at $11.6 million, down 69.5% from the prior year.
• Cost of Revenue for Q1 2026 stood at $11.5 million, up from $3.8 million in the prior quarter.
• Over the last five years, Cost of Revenue for NAGE reached as high as $12.1 million in Q3 2025 and fell as low as $2.1 million in Q2 2024.
• Historically, Cost of Revenue has averaged $7.4 million across 5 years, with a median of $8.0 million in 2023.
• Across the five-year window, Cost of Revenue plunged 73.37% in 2024 and surged 364.0% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $9.0 million in 2022, then declined by 8.03% to $8.3 million in 2023, then soared by 32.32% to $10.9 million in 2024, then sank by 64.87% to $3.8 million in 2025, then surged by 199.51% to $11.5 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $11.5 million in Q1 2026, $3.8 million in Q4 2025, and $12.1 million in Q3 2025.